Research programme: small molecule therapeutics - C4X Discovery

Drug Profile

Research programme: small molecule therapeutics - C4X Discovery

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator C4X Discovery
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; Genome modulators; Glucagon like peptide 1 receptor agonists; Interleukin 17 receptor antagonists; KEAP1 protein modulators; NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Chronic obstructive pulmonary disease; Inflammation; Neurodegenerative disorders; Type 2 diabetes mellitus

Most Recent Events

  • 28 Sep 2016 C4X Discovery and Evotec agree to co-develop small molecule therapeutics
  • 06 Sep 2016 C4XD and Structural Genomics Consortium agree to co-develop small molecule therapeutics in United Kingdom for Cancer
  • 06 Sep 2016 C4X discovery has patent protection for Conformetrix technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top